Showing 4851-4860 of 5771 results for "".
- AOA Receives Department of Justice Approval to Expand Group Purchasing Activities for Its AOAExcel Membershttps://modernod.com/news/aoa-receives-department-of-justice-approval-to-expand-group-purchasing-activities-for-its-aoaexcel-members/2477244/The Department of Justice (DOJ) announced January 15 that it will not challenge a proposal by the American Optometric Association to expand its group purchasing organization’s (GPO) activities to include the purchase of optometric products for resale to consumers, specifically eyeglass lenses, fr
- Hoya Surgical Optics Launches Joint Venture With GeMax in Chinahttps://modernod.com/news/hoya-surgical-optics-launches-joint-venture-with-gemax-in-china/2477238/Hoya Surgical Optics (HSO) announced a new joint venture with GeMax, a specialty promotion service provider of IOLs with a strong market position and reputation in China, covering more than 630 major hospitals in 32 provinces. The joint venture will be named Hoya GeMax Medical. HSO will be the ma
- Mojo Vision Developing Smart Contact Lenshttps://modernod.com/news/mojo-vision-developing-smart-contact-lens/2477237/Mojo Vision announced it is building what it calls the “world’s first true smart contact lens,” called the Mojo Lens. Mojo Lens is a contact lens with a built-in display that gives people useful and timely information without forcing them to look down at a screen or losing focus on th
- Bausch + Lomb Secures Additional Approvals of Vyzulta in Hong Kong and Argentinahttps://modernod.com/news/bausch-lomb-secures-additional-approvals-of-vyzulta-in-hong-kong-and-argentina/2477234/Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Hong Kong and Argentina. With these approvals, Vyzulta is now approved for commercialization in a total of five countries and territories. Vyzulta is indi
- Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma’s Impact on Daily Livinghttps://modernod.com/news/allergan-teams-up-with-super-bowl-mvp-von-miller-to-raise-awareness-of-glaucomas-impact-on-daily-living/2477236/Allergan announced a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker, and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the ‘My Glaucoma’ campaign, Mr. Miller wil
- Kala Pharmaceuticals Completes of Enrollment of STRIDE 3 Trial for Eysuvis for Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-announces-completion-of-enrollment-of-stride-3-trial-for-eysuvis-for-dry-eye-disease/2477232/Kala Pharmaceuticals announced that it has completed enrollment in its STRIDE 3 (STRIDE – Short Term Relief In Dry Eye) phase 3 clinical trial for KPI-121 0.25%, its product candidate for the short-term treatment of dry eye disease. If approved, Kala plans to commercialize KPI-121 0.25% under the
- Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint-in-phase-2-mystic-trial-in-subjects-with-dry-eye-disease/2477225/Oyster Point Pharma announced positive topline results from its phase 2 MYSTIC study in dry eye disease. Results showed a statistically significant improvement in Schirmer’s score from baseline at Day 84 in both doses as compared to control.
- Staar Surgical Gains Supplemental Lens Approval for EVO Visian ICL to Target Post-Cataract Market Opportunityhttps://modernod.com/news/staar-surgical-gains-supplemental-lens-approval-for-evo-visian-icl-to-target-post-cataract-market-opportunity/2477226/Staar Surgical announced it has gained CE Mark approval for use of its ICL as a supplemental or “piggyback” lens in post-cataract IOL surgery patients (pseudophakics). A supplemental EVO ICL is placed in front of the cataract IOL lens in post-cataract patients, just like the EVO ICL is placed in
- The American Optometric Association (AOA) Launches Nationwide Campaign to Make 2020 the Year of the Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-launches-nationwide-campaign-to-make-2020-the-year-of-the-eye-exam/2477227/The American Optometric Association (AOA) announced the official launch of the #2020EyeExam campaign to make eye health and vision care a national priority in 2020. The public awareness campaign underscores the importance of receiving an in-person comprehensive eye examination with an AOA doctor
- Bausch + Lomb Secures Approval of Vyzulta in Mexicohttps://modernod.com/news/bausch-lomb-secures-approval-of-vyzulta-in-mexico/2477224/Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Mexico. The approval in Mexico follows approvals of Vyzulta in the United States and Canada.